Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.
Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.
LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.
Source: Read Full Article
Lates News:
-
65% Of Bitcoin Supply Unmoved In Over A Year, Signaling Bottom And Looming Upwards Price Action
-
$BTC: Peter Schiff Calls Bitcoin Trading Above $21K a “Sucker’s Rally”
-
Coinbase CEO Thinks Brazil and Argentina Should ‘Consider Moving to Bitcoin’
-
Cryptos Brace For Debt Deal Outcome
-
Hopes Of A Spot Bitcoin ETF Dashed As SEC Again Extends ARK Deadline To January